Publicacións en colaboración con investigadores/as de University Hospital of Bern (65)

2024

  1. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial

    European Journal of Internal Medicine

  2. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

  3. Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 7, pp. 890-903

  4. TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation

    European heart journal, Vol. 45, Núm. 8, pp. 586-597

  5. Tricuspid valve disease and cardiac implantable electronic devices

    European Heart Journal, Vol. 45, Núm. 5, pp. 346-365

2023

  1. 2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry

    International Journal of Cardiology, Vol. 390

  2. Symptomatic vs. non-symptomatic device-related thrombus after LAAC: a sub-analysis from the multicenter EUROC-DRT registry

    Clinical Research in Cardiology, Vol. 112, Núm. 12, pp. 1790-1799

  3. Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads

    Journal of Interventional Cardiac Electrophysiology, Vol. 66, Núm. 7, pp. 1589-1600

2022

  1. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk

    Journal of the American College of Cardiology, Vol. 80, Núm. 13, pp. 1220-1237

  2. Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry

    Clinical Research in Cardiology, Vol. 111, Núm. 11, pp. 1276-1285

  3. Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction

    European heart journal, Vol. 43, Núm. 7, pp. 641-650

  4. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  5. Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry

    Circulation. Cardiovascular interventions, Vol. 15, Núm. 3, pp. e011302

  6. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  7. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  8. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry

    European Journal of Preventive Cardiology, Vol. 29, Núm. 15, pp. 1945-1954

  9. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience

    European Journal of Heart Failure, Vol. 24, Núm. 5, pp. 899-907

2021

  1. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

    Circulation, Vol. 144, Núm. 15, pp. 1196-1211

  2. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

  3. Corrigendum to “European Resuscitation Council Guidelines 2021: Executive summary” [Resuscitation (2021) 1–60] (Resuscitation (2021) 161 (1–60), (S0300957221000551), (10.1016/j.resuscitation.2021.02.003))

    Resuscitation